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ABSTRACT
Introduction: Ex vivo normothermic perfusion (EVNP)
is a novel technique that reconditions the kidney and
restores renal function prior to transplantation. Phase I
data from a series of EVNP in extended criteria donor
kidneys have established the safety and feasibility of
the technique in clinical practice.
Methods and analysis: This is a UK-based phase II
multicentre randomised controlled trial to assess the
efficacy of EVNP compared with the conventional static
cold storage technique in donation after circulatory death
(DCD) kidney transplantation. 400 patients receiving a
kidney from a DCD donor (categories III and IV,
controlled) will be recruited into the study. On arrival at the
transplant centre, kidneys will be randomised to receive
either EVNP (n=200) or remain in static cold storage
(n=200). Kidneys undergoing EVNP will be perfused with
an oxygenated packed red cell solution at near body
temperature for 60 min prior to transplantation. The
primary outcome measure will be determined by rates of
delayed graft function (DGF) defined as the need for
dialysis in the first week post-transplant. Secondary
outcome measures include incidences of primary non-
function, the duration of DGF, functional DGF defined as
<10% fall in serum creatinine for 3 consecutive days in the
first week post-transplant, creatinine reduction ratio days 2
and 5, length of hospital stay, rates of biopsy-proven acute
rejection, serum creatinine and estimated glomerular
filtration rate at 1, 3, 6 and 12 months post-transplant and
patient and allograft survival. The EVNP assessment score
will be recorded and the level of fibrosis and inflammation
will also be measured using tissue, blood and urine
samples. Ethics and dissemination. The study has been
approved by the National Health Service (NHS) Health
Research Authority Research Ethics Committee. The
results are expected to be published in 2020.
Trial registration number: ISRCTN15821205;
Pre-results.
INTRODUCTION
Kidney transplantation continues to be
limited by a shortage of organ donors. In
response to this, there has been an increase
in the use of kidneys from marginal donors
and a signiﬁcant proportion of transplant
kidneys are now provided by donation after
circulatory death (DCD) donors.1 DCD
kidneys inevitably sustain a warm ischaemic
insult prior to retrieval and 50–60% of these
kidneys have delayed graft function (DGF)
after transplantation.1 DGF is associated with
an increased risk of acute rejection, longer
in-patient stay and therefore greater cost, and
may also reduce allograft survival.1–7
Moreover, when compared with standard cri-
teria donors, DCD kidneys are three times
more likely to be declined for transplant-
ation due to concerns over their quality.8 9
Strengths and limitations of this study
▪ This is a large multicentre randomised controlled
trial. It will provide evidence of the effect of ex
vivo normothermic perfusion (EVNP) on early
graft function in donation after circulatory death
kidney transplantation.
▪ The secondary objectives will allow us to
examine the impact of EVNP on rates of acute
rejection and longer term graft function and
survival.
▪ Tissue, blood and urine samples will enable a
more in-depth analysis of the effects of EVNP on
ischaemia reperfusion.
▪ The limitation of this study is the lack of blind-
ing. Owing to the nature of the technique and in
order to report safety outcomes, it is not pos-
sible to blind the surgical team to the allocation
of the kidney.
▪ Delayed graft function, defined as dialysis within
the first week of transplantation, is subjective.
However, it is the best accepted measure of early
graft function.
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Organ preservation has traditionally relied on hypo-
thermic techniques based on the principle that refriger-
ation reduces cellular metabolism and tissue oxygen
requirements. The problem is that in the anoxic hypo-
thermic environment anaerobic cellular respiration con-
tinues, albeit at a slow pace. Oxidative phosphorylation
is uncoupled and mitochondrial ATP production by che-
miosmosis ceases.10 ATP continues to be generated at a
much slower rate by substrate-based phosphorylation in
the glycolytic pathway. This leads to depletion of intra-
cellular ATP stores. Anaerobic respiration generates
lactic acid leading to worsening intracellular acidosis
and eventually loss of cell viability.10 The initial warm
ischaemic injury sustained by DCD kidneys makes them
less tolerant of cold ischaemic injury during hypother-
mic preservation.11 12
Normothermic perfusion techniques offer an alterna-
tive form of organ preservation and resuscitation that
has the potential to limit some of the effects of hypo-
thermic preservation techniques.13 Ex vivo normother-
mic perfusion (EVNP) is a novel technique that may
help to recondition ischaemically injured kidneys prior
to transplantation.13 The aim of EVNP is to restore
metabolism and function to the kidney prior to trans-
plantation by circulating a warm oxygenated red cell-
based solution through the kidney.
EVNP has recently been introduced into clinical prac-
tice for kidneys from marginal donors.13–17 The early
experience of renal transplantation after EVNP shows
that the technique is feasible, safe and may improve
early graft function.
This study will investigate the effect of 60 min EVNP
in kidneys from DCD donors compared with the trad-
itional technique of static cold storage.
The primary outcome measure will be DGF deﬁned as
the need for dialysis in the ﬁrst 7 days post-
transplantation. Secondary outcome measures will
include more sensitive measures of renal function over
the ﬁrst 7 days post-transplant, length of hospital stay,
graft and patient survival at 1 year and rates of acute rejec-
tion. Fibrosis, inﬂammatory markers and urinary biomar-
kers will also be examined in tissue, blood and urine.
METHODS
Study type
A randomised controlled, open-label trial of the effect
of EVNP on initial graft function in DCD kidney trans-
plant. Figure 1 summarises the design of the trial.
Eligibility
Patients will be eligible for the trial if they meet the fol-
lowing criteria: patients undergoing a DCD kidney trans-
plantation (Maastricht categories III and IV); the donor
and recipient must be ≥18 years and it must be the
patient’s ﬁrst or second kidney transplant.
Written informed consent will be taken from all
patients included in the trial by a qualiﬁed member of
the study team. Patients will not be eligible if the donor
or recipient is under the age of 18 years, the DCD
donor is in Maastricht categories I and II, patients
receiving a third or subsequent kidney transplant,
patients receiving multiorgan transplants, for example,
simultaneous pancreas–kidney transplantation, patients
receiving dual kidney transplants, paediatric en-bloc
kidney transplants or kidneys that have been preserved
by hypothermic machine perfusion. There will be four
participating centres in the UK: Cambridge (lead),
Newcastle, Guy’s and Edinburgh.
Randomisation
Patients will be allocated at random in a 1:1 ratio to
either static cold storage (CS) plus 1 hour of EVNP
(n=200) or CS (n=200) only. A patient information sheet
will be given to potential recruits on admission for DCD
kidney transplantation and written informed consent will
then be obtained (see online supplementary appendices
1 and 2). Randomisation will be performed after the
transplant recipient and kidney have both arrived in the
transplanting centre and a ﬁnal decision to proceed with
transplantation has been made by a member of the study
team. The randomisation will be performed on a web-
based system (sealed envelope) which uses a computer-
generated randomisation sequence. In cases where
paired kidneys from the same donor are transplanted in
the same centre, one kidney from the pair will be ran-
domly allocated to CS and the other to EVNP. In these
cases, the randomisation will also determine which
kidney (right or left) will be transplanted ﬁrst. Owing to
the nature of the trial, no one is blinded to treatment
allocation.
Multiple vessels
DCD kidneys with multiple renal arteries will not be
excluded from the trial as EVNP is technically possible
in such kidneys. A cannula that preserves the carrel
patch or a graft reconstruction using donor vessels will
be used where possible. Nonetheless, EVNP may prove
to be very difﬁcult in kidneys with particularly complex
vascular anatomy. If such a kidney is randomised to
EVNP, then the local investigator may decide to use CS
alone. Nonetheless, the recipient will be analysed in the
EVNP arm of the study in line with the intention-to-treat
basis. As per protocol, analysis will also be performed to
assess the effects of the actual preservation method.
Kidney retrieval
All kidneys will be retrieved by the UK national retrieval
teams. Following in situ ﬂushing of the abdominal
organs with hyperosmolar citrate (HOC) solution or
University of Wisconsin (UW) solution, kidneys will be
removed and then placed individually in preservation
solution and packed in ice. The perfusion solution used
will be recorded.
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vivo normothermic perfusion
The EVNP circuit has been designed using paediatric
cardiopulmonary bypass technology (Medtronic,
Watford, UK) and consists of a centrifugal blood pump
(Bio-pump 560), a heat exchanger, a venous reservoir
(Medtronic), 1/4 inch Polyvinyl chloride (PVC) tubing
and an Afﬁnity membrane oxygenator (Medtronic). The
hardware includes a speed controller, a TX50P ﬂow
transducer and a temperature probe (Cole-Parmer,
London, UK). Two infusion pumps are also incorpo-
rated into the system.
Perfusate
The circuit will be primed with perfusate solution (Ringer’s
solution, Baxter Healthcare, Thetford, Norfolk, UK) and
one unit of O-positive or O-negative packed red cells from
the blood bank. Mannitol 10% (Baxter Healthcare),
dexamethasone 8 mg (Organon Laboratories, Cambridge,
UK) and heparin (CP Pharmaceuticals, Wrexham, UK) will
be added to the perfusate. Sodium bicarbonate 8.4%
(Fresenius Kabi, Cheshire, UK) will be added to normalise
the pH. A nutrient solution (Synthamin 17, Baxter
Healthcare) with sodium bicarbonate 8.4%, insulin (Novo
Nordisk, Denmark) and multivitamins (Cernevit, Baxter
Healthcare) will be infused into the circuit at a rate of
20 mL/hour. Prostacyclin 0.5 mg (Flolan, Glaxo-Wellcome,
Middlesex, UK) will be infused into the arterial arm of the
circuit at a rate of 5 mL/hour and glucose 5% (Baxter
Healthcare) at 5 mL/hour. Ringer’s solution will be used to
replace urine output mL for mL.
Perfusion chamber
Kidneys undergoing EVNP will be placed in a custom-
designed sterile perfusion chamber and the renal artery
Figure 1 Trial design. CS, cold
storage; DCD, donation after
circulatory death; DGF, delayed
graft function; eCRF, electronic
case report form; eGFR,
estimated glomerular filtration
rate; fDGF, functional DGF;
EVNP, ex vivo normothermic
perfusion.
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and vein will be cannulated and primed with cold 0.9%
sodium chloride.
Perfusion parameters
Kidneys will be perfused at a set mean arterial pressure
(75 mm Hg). The plasma-free red cell-based perfusate
will be circulated from the venous reservoir through the
centrifugal pump into the membrane oxygenator, where
it is oxygenated and also warmed to 35–36°C. It will then
ﬂow through the arterial limb of the circuit to the renal
artery. Venous return from the renal vein will be fed
back into the reservoir.
Renal blood ﬂow (RBF) will be monitored continu-
ously during EVNP. Intrarenal resistance will be calcu-
lated (mean arterial pressure/RBF) every 5 min until
the end of perfusion. The total urine output will be
recorded. Blood gas analysis will be used to measure the
acid–base balance pre-EVNP and post-EVNP.
Postperfusion
After EVNP, kidneys will be ﬂushed with ∼500 mL of
cold (4°C) HOC (Baxter Healthcare, UK) to remove the
perfusate and then placed back in ice until transplanted.
Prior to transplantation, the arterial Carrel patch may
have to be excised along with a short segment of vein in
order to remove the cannula ligature sites.
EVNP assessment scoring
An assessment score will be recorded for all kidneys
undergoing EVNP but will not be used to make deci-
sions about the suitability of kidneys for transplantation
(table 1).13
Transplantation
This will be performed using standard techniques.
Anaesthesia will be given according to local protocols.
Kidneys will be transplanted into either iliac fossa with
anastomosis of the artery to the common, external or
internal iliac arteries. The vein will be anastomosed to
either the common or the external iliac vein. The
ureteric anastomosis will be performed as an extravesical
onlay over a double J stent.
Immunosuppressive therapy
All centres will use similar immunosuppressive protocols
as follows: patients will receive 20 mg of basiliximab
intravenously pretransplant and 20 mg intravenously on
postoperative day 4. Patients will receive a bolus of
methylprednisolone intravenously at induction of anaes-
thesia using a dosage according to local practice. The
post-transplant oral prednisolone regimen will also be
according to local practice.
Patients may be treated with either tacrolimus or cyclo-
sporine according to local protocols. There will be no
restriction on the formulation of the prescribed calci-
neurin inhibitors. Tacrolimus will be prescribed to achi-
eve target trough levels of 3–12 ng/mL. Cyclosporine
will be prescribed to achieve target trough levels of 100–
250 ng/mL. The ﬁrst dose of calcineurin inhibitor may
be given preoperatively or postoperatively. All patients
will receive mycophenolate as either mycophenolate
mofetil (Cellcept) at a starting dose of at least 1 g/day
or mycophenolate sodium (Myfortic) starting at a dose
of at least 720 mg/day.
Antimicrobial and antithrombotic prophylaxis will be
given according to local protocols. It is expected that
patients will also receive prophylaxis against Pneumocystis
jirovecii pneumonia, oral candidiasis and cytomegalovirus
(valganciclovir for 100 days in CMV-positive donor to
CMV-negative recipient transplants).
Outcomes
Primary outcome measure
The primary outcome measure is DGF deﬁned as the
need for dialysis in the ﬁrst 7 days post-transplantation.18
Secondary outcome measures
The secondary outcome measures include incidences of
primary non-function (PNF) deﬁned as the permanent
lack of allograft function from the time of transplant-
ation (This will include graft losses due to irreversible
rejection and vascular thrombosis. The cause of graft
loss will be recorded.); the duration of DGF in days;
functional DGF (fDGF) deﬁned as <10% fall in serum
creatinine for 3 consecutive days in the ﬁrst week post-
transplant; creatinine reduction ratio day 2 (CRR2=
creatinine day 1−creatinine day 2/creatinine day 1) and
CRR5 (CRR5=pretransplant creatinine−creatinine day
5/pretransplant creatinine);19 length of hospital stay,
rates of biopsy-proven acute rejection rate and measures
of renal function (serum creatinine and estimated glom-
erular ﬁltration rate (eGFR)) at 1, 3, 6 and 12 months
post-transplant. Patient survival (time from transplant to
death) and allograft survival (time from transplant to
graft loss or return to dialysis) will be recorded. The
Table 1 Ex vivo normothermic perfusion (EVNP) score
EVNP score
Macroscopic appearance Points
Excellent perfusion with global and even pink
appearance
1 point
Moderate perfusion with some areas of patchy
or mottled perfusion
2 points
Poor perfusion with a globally mottled and
purple appearance
3 points
Mean renal blood flow (mL/min/100 g)
<50 mL/min/100 g
1 point
Mean renal blood flow (mL/min/100 g)
>50 mL/min/100 g
0 point
Total urine output (mL) <43mL/hour 1 point
Total urine output (mL) >43mL/hour 0 point
Scores for macroscopic appearance, renal blood flow and urine
output will be added to yield an overall assessment score ranging
from 1 (the highest quality) to 5 (the lowest quality).
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EVNP score will be calculated for each kidney undergo-
ing EVNP (table 1). The predictive value of this assess-
ment score on graft function and outcome will be
evaluated. A clinical decision on the suitability of the
kidney for transplantation will be made using normal
criteria prior to perfusion. However, the EVNP assess-
ment score will be taken into consideration. Arterial and
venous samples will be collected during perfusion and
used to measure oxygen consumption, acid–base
balance and concentrations of sodium, potassium,
glucose, lactate and calcium. Concentrations of sodium
and potassium will also be measured in the urine at the
end of EVNP.
Renal fibrosis
One of the most common causes of graft failure after
transplantation is the development of chronic allograft
nephropathy.20 The aim of this study is to determine if
EVNP can slow the progression of ﬁbrosis. Biopsies of the
kidney will be taken pretransplant and after 3 months.
Biopsies will be ﬁxed in formalin and parafﬁn embedded
cut sections of the graft will be stained with sirius red
(stains for collagen III). The degree of ﬁbrosis will be
quantiﬁed using computerised digital image analysis.
Injury markers
Ischaemia reperfusion injury is a leading cause of early
graft dysfunction. The aim of this study is to determine
if EVNP can reduce the amount of inﬂammation and
injury after transplantation. Blood and urine samples
will be collected pretransplant and post-transplant and
used to measure inﬂammation (inﬂammatory cyto-
kines: interleukin-6 (IL-6), tumour necrosis factor-α,
IL-8) and kidney injury (neutrophil gelatinase-
associated lipocalin, liver fatty acid binding protein).
Further biopsies of the kidney will be taken and snap
frozen in liquid nitrogen or stored in RNA later, preim-
plantation and 30 min post-transplant. These will be
used for light microscopy and RNA sequencing to
determine the degree of acute tubular injury, measure
inﬂammatory cytokines and downstream signalling
molecules such as vascular endothelin growth factor
(VEGF) and Erythropoietin (EPO).
Sample storage
Samples will be stored in the clinical and research
laboratories within the participating centres. Samples
will be coded and donor identiﬁable material will only
be available to the principal investigator (PI) and the
research team at the participating centres. Samples are
appropriately labelled in accordance with the trial proce-
dures to comply with the 1998 Data Protection Act.
Biological samples collected from participants as part of
this trial will be transported, stored, accessed and pro-
cessed in accordance with national legislation relating to
the use and storage of human tissue for research pur-
poses and such activities shall at least meet the
requirements as set out in the 2004 Human Tissue Act
and the 2006 Human Tissue (Scotland) Act.
On completion of the trial, samples will be disposed
of in accordance with the Human Tissue Authority’s
Code of Practice.
Statistics
Sample size determination
The trial size was calculated with respect to the primary
end point, which is DGF deﬁned as the requirement for
dialysis in the ﬁrst 7 days post-transplantation. Based on
5 years of data from the three participating centres, the
overall rate of DGF in DCD kidney transplants is 50%.
In a pilot series of kidney transplants from extended cri-
teria donors (ECD), 18 kidneys undergoing CS followed
by 1 hour of EVNP were compared with a historical
control group of 47 ECD transplants after CS alone. The
DGF rates were 1/18 (6%) in the EVNP group com-
pared with 17/47 (36%) in the CS group.14
Using a ﬁxed sample size study, with interim analyses
after 125 and 250 patients have been enrolled and
reached 365 days post-transplant, a total of 376 patients
receiving a DCD kidney (Maastricht categories III and
IV controlled donors) will be required to detect a 30%
relative reduction in DGF (from 50% to 35%) with a
power of 80% and a statistical signiﬁcance of α=0.05. To
allow for a study withdrawal rate of 6%, a total of 400
patients will be recruited.
Interim analysis
Two interim analyses will be performed during the study
period. The ﬁrst of these will be after 125 patients have
received a transplant and reached 7 days post-transplant
and the second after 250 patients have been recruited
(and have received a transplant and reached 7 days
post-transplant).
Analysis population and principles
The population used for efﬁcacy analyses will be an
intent-to-treat population including all eligible rando-
mised patients. This will be the primary analysis for the
trial. Characteristics of all randomised patients will be
tabulated by arm of the trial to describe the cohort.
The primary and secondary outcomes will also be ana-
lysed per protocol.
Analysis of primary and secondary outcomes
The analyses will be described in detail in a full statistical
analysis plan. This section summarises the main issues. A
full statistical analysis plan will be drawn up prior to the
ﬁrst interim analysis.
Primary analysis
The number of patients who experience DGF between
the two groups will be compared using a logistic regres-
sion model adjusting for cold ischaemic time and
donor age.
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Secondary outcomes
PNF: The number of patients experiencing PNF in each
arm will be compared using Fisher’s exact text. The cause
of graft loss will be tabulated by arm. The duration of
DGF in days will be summarised using the Kaplan-Meier
estimate of the duration of DGF for all those who experi-
enced DGF and compared using a log-rank test.
Outcome measures: The number of patients that experi-
ence functional DGF will be compared using Fisher's
exact test. The CRR2 and CRR5 will be compared by
arm using a two-sample t-test. The length of hospital
stay, deﬁned from admission to discharge, will be esti-
mated using the Kaplan-Meier method, with deaths in
hospital censored, and compared between arms using
the log-rank test.
Biopsy-proven acute rejection rate: The number of patients
in each arm will be compared using Fisher’s exact test.
Longitudinal changes in serum creatinine and eGFR will
be separately assessed at 1, 3, 6 and 12 months post-
transplant and mean values compared using two-way ana-
lysis of variance with repeated measures for patients in
each arm of the trial. Any difference between arms in the
way serum creatinine and eGFR change over time will
also be assessed using this model. Patient survival (time
from transplant to death) and allograft survival (time
from transplant to graft loss or return to dialysis) will be
analysed using a Kaplan-Meier estimate of the probability
of an event after 12 months and a log-rank test. Time to
graft loss or return to dialysis will be modelled.
Analysis population and missing data
Normally if a patient experiences DGF, they would
remain in hospital for a minimum of 7 days. Hence, for
pragmatic reasons, if a patient is discharged from the
hospital prior to 7 days post-transplant and the patient is
known to be alive at 7 days post-transplant, then such
patients will be imputed to have not experienced DGF.
Some patients may also withdraw consent, be withdrawn
or die during the conduct of the trial. In any of these
cases, it is impossible to know whether such patients are
either less or more likely to experience DGF had they
not experienced early censoring. Sensitivity analyses will
be performed to account for this.
Safety outcomes
Incidences of acute rejection, renal artery or renal vein
thrombosis, complications of the renal transplant biopsy
and the number of hospital admissions for any recog-
nised complication of renal transplantation and
immunosuppression will be summarised by arm.
The University of Cambridge and Cambridge
University Hospital National Health Service (NHS)
Foundation Trust will be the sponsor for this study. A
Trial Steering Committee will meet six monthly to review
the trial, monitor recruitment rates to consider protocol
amendments and provide advice. A Trial Management
Group will be responsible for the Ethics Committee
application and the production of reports and the
day-to-day running of the trial. A Data Monitoring
Committee will consist of three independent members
with expertise in renal transplantation, clinical trials and
statistics. They will meet at least annually to review data,
primarily concentrating on patient safety.
Data handling
A data will be collected prospectively and recorded on
the electronic case report forms. The data will be moni-
tored by the trial manager and audited each month.
Each participant will be allocated a unique study
number and will be identiﬁable by this number through-
out the course of the study. This number will be used on
all documentation and during analysis of the results.
Tissue, blood and urine samples will be coded with a
unique number. Any data transferred will be carried out
under the NHS Code of Practice on Conﬁdentiality.
Ethical considerations
The study protocol and trial documents including the
consent form and participant information sheet have
been approved by the NHS Health Research Authority
East of England, Cambridge Central Research
Committee (15/EE/0356). Approval has also been
granted by the NHS Research & Development (R&D)
department and will be sought at each participating
centre. Substantial amendments will require ethical
review. Amendments will also need to be reviewed and
accepted by the NHS R&D departments before they can
be implemented in practice at sites.
Insurance of negligent or non-negligent harm will be
covered under the University’s clinical trial policy.
There are no conﬂicts of interest for the PIs or
members of the study team.
Dissemination
The results of the study will be submitted for peer
review for publication in a scientiﬁc journal and will also
be presented at national and international meetings.
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